This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide financial and corporate updates when it releases second-quarter 2020 results on Jul 30.
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Emergent (EBS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?
by Zacks Equity Research
On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
by Zacks Equity Research
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
by Zacks.com
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -23.91% and -3.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
BorgWarner (BWA) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Heightening coronavirus fears, along with supply-chain inefficiencies and higher research and development costs, are likely to have clipped BorgWarner's (BWA) margins in Q1.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 8.11% and 2.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
by Zacks Equity Research
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.